Event
Axxam sponsors the FEBS/EMBO Workshop on Ion Channels and Disease
Date: 13-19 May 2026
Location: Erice, Italy
Axxam is proud to support the upcoming FEBS/EMBO Workshop focused on ion channels and their role in human disease.
This scientific event brings together researchers working across ion channel biology, pharmacology, structural biology, electrophysiology, and drug discovery to discuss emerging advances, technologies, and therapeutic opportunities in the field.
As a company active in early drug discovery and assay development, Axxam recognizes the critical importance of ion channels as therapeutic targets across neuroscience, pain, cardiovascular disorders, rare diseases, and metabolic conditions.
Supporting innovation in ion channel research
Ion channels remain among the most biologically relevant and technically challenging target classes in drug discovery.
Recent advances in:
- electrophysiology
- human-relevant cellular models
- high-content functional assays
- automated screening technologies
- AI-supported data analysis
- phenotypic profiling approaches
are expanding the ability to investigate channel function and identify novel modulators with greater precision and translational relevance.
Scientific workshops such as the FEBS/EMBO meeting play an important role in fostering collaboration and accelerating innovation across academia and industry.
Axxam’s expertise in ion channel drug discovery
Axxam has developed extensive expertise in electrophysiology-based approaches to support ion channel drug discovery and functional characterization programs.
Our integrated capabilities combine automated electrophysiology platforms, advanced cellular assays, and disease-relevant models to investigate ion channel activity, pharmacology, and mechanism of action across multiple therapeutic areas.
In addition to conventional electrophysiology workflows, Axxam has established specialized expertise in organellar electrophysiology, enabling the direct investigation of intracellular ion channels localized within organelles such as lysosomes.
By integrating electrophysiology with human iPSC-derived models, high-content imaging, and phenotypic profiling, Axxam supports deeper mechanistic understanding of complex ion channel biology and emerging therapeutic targets, including those involved in neurodegenerative and rare diseases.
About Axxam
Axxam is a Contract Research Organization (CRO) supporting early drug discovery through integrated assay development, screening, compound management, and advanced in vitro platforms.